Clinical trial
Liposomal Doxorubicin and Etoposide in Treating Patients With Recurrent or…
NCT00003380 · Gynecologic Oncology Group, Other · Terminated
Key facts
| NCT number | NCT00003380 |
|---|---|
| Title | Liposomal Doxorubicin and Etoposide in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, or Peritoneal Cancer |
| Official title | A Phase I Study of Liposomal Doxorubicin (Doxil) and Prolonged Etoposide As Second Line Therapy in Ovarian, Tubal and Peritoneal Carcinoma |
| Lead sponsor | Gynecologic Oncology Group, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Terminated |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer |
| Intervention type | Drug |
| Interventions | etoposide, pegylated liposomal doxorubicin hydrochloride |
| Start date | May 1, 1998 |
| Primary completion | Jul 1, 2002 |
| First posted | Aug 16, 2004 |
| Last update posted | Jun 10, 2013 |
| Countries | Canada, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: